KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Operations (2016 - 2025)

Arbutus Biopharma's Cash from Operations history spans 13 years, with the latest figure at 5817000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 71.95% year-over-year to 5817000.0; the TTM value through Sep 2025 reached 45272000.0, up 36.97%, while the annual FY2024 figure was 64850000.0, 24.54% up from the prior year.
  • Cash from Operations for Q3 2025 was 5817000.0 at Arbutus Biopharma, up from 15749000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 20619000.0 in Q1 2022 and bottomed at 27301000.0 in Q1 2023.
  • The 5-year median for Cash from Operations is 17292000.0 (2023), against an average of 15191105.26.
  • The largest annual shift saw Cash from Operations soared 215.31% in 2022 before it crashed 232.41% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 19606000.0 in 2021, then rose by 13.34% to 16990000.0 in 2022, then fell by 1.78% to 17292000.0 in 2023, then skyrocketed by 40.35% to 10315000.0 in 2024, then soared by 43.61% to 5817000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Cash from Operations are 5817000.0 (Q3 2025), 15749000.0 (Q2 2025), and 13391000.0 (Q1 2025).